At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 18 enrolled
Drug / intervention
Sitagliptin +2 moredrug
Likely dose
Sitagliptin 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Anti-Diabetic Medications to Fight Parkinson's Disease and Lewy Body Dementia
In Brief
A Phase 4 clinical trial evaluating Sitagliptin, Dapagliflozin, and 1 other intervention for Lewy Body Dementia and Parkinson Disease. Completed, enrolled 18 participants across 1 site.
Detailed Summary
The purpose of this study is to test the hypothesis that DPP4 inhibitors and SGLT2 inhibitors are well tolerated and have beneficial neurological effects, specifically for Parkinson's disease and Lewy body dementia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLewy Body Dementia, Parkinson Disease
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20252026
First PostedFeb 2024
Enrollment StartMay 2024
Primary CompletionJan 2025
TodayJul 2026
First PostedFeb 16, 2024
Enrollment StartMay 7, 2024
Primary CompletionJan 8, 2025
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 2.4 years ago
Interventions
Sitagliptindrug
100 mg once daily, oral
Dapagliflozindrug
10 mg once daily, oral
Placebodrug
Once daily, oral. Looks similar to the study drug, but it contains no active ingredient.